EVs require 180 lbs of copper.
Investors must see the miner that could power the whole industry.
Get the Full Story. This is Exciting!

RAIN Insider Trading (Rain Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $47,593,524.45
Insider Selling (Last 12 Months): $0.00

Rain Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Rain Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rain Therapeutics Share Price & Price History

Current Price: $15.45
Price Change: Price Increase of +0.44 (2.93%)
As of 09/24/2021 02:39 PM ET

This chart shows the closing price history over time for RAIN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
See who's transforming livestreaming and digital coins.
The world is on notice. This revolutionary platform is combining livestreaming with social media and digital currencies.

With rapid expansion and revenue growth, this disruptor has livestreaming and digital mining operations in the palm of its hand.
Don't miss out on this historic play.

Rain Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/21/2021Franklin M BergerDirectorBuy3,786$14.30$54,139.80View SEC Filing Icon  
9/13/2021Bvf Partners L P/IlDirectorBuy392,269$16.49$6,468,515.81View SEC Filing Icon  
7/6/2021Bvf Partners L P/IlDirectorBuy269,723$15.25$4,113,275.75View SEC Filing Icon  
7/1/2021Bvf Partners L P/IlDirectorBuy317,279$15.65$4,965,416.35View SEC Filing Icon  
5/24/2021Bvf Partners L P/IlDirectorBuy1,361$15.90$21,639.90View SEC Filing Icon  
5/21/2021Bvf Partners L P/IlDirectorBuy121,986$15.94$1,944,456.84View SEC Filing Icon  
5/13/2021Bvf Partners L P/IlDirectorBuy58,000$14.26$827,080.00View SEC Filing Icon  
4/27/2021Boxer Capital, LlcDirectorBuy1,025,000$17.00$17,425,000.00View SEC Filing Icon  
4/27/2021Perceptive Advisors LlcMajor ShareholderBuy550,000$17.00$9,350,000.00View SEC Filing Icon  
4/23/2021Boxer Capital, LlcDirectorBuy150,000$16.16$2,424,000.00120,000View SEC Filing Icon  
See Full Table
Insider Buying at Rain Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Rain Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Rain Therapeutics (NASDAQ:RAIN)

57.18% of Rain Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RAIN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Rain Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/17/2021Woodline Partners LP119,700$1.86M0.0%N/A0.452%Search for SEC Filing on Google Icon
8/17/2021Zimmer Partners LP10,000$0.16M0.0%N/A0.038%Search for SEC Filing on Google Icon
8/17/2021Perceptive Advisors LLC2,537,019$39.43M0.5%N/A9.580%Search for SEC Filing on Google Icon
8/17/2021Samsara BioCapital LLC1,637,308$25.44M3.1%N/A6.182%Search for SEC Filing on Google Icon
8/17/2021Logos Global Management LP780,331$12.13M1.0%N/A2.947%Search for SEC Filing on Google Icon
8/17/2021Acuta Capital Partners LLC162,245$2.52M1.0%N/A0.613%Search for SEC Filing on Google Icon
8/17/2021BVF Inc. IL1,945,949$30.24M1.1%N/A7.348%Search for SEC Filing on Google Icon
8/17/2021Boxer Capital LLC1,175,000$18.26M0.6%N/A4.437%Search for SEC Filing on Google Icon
8/16/2021California State Teachers Retirement System10,258$0.16M0.0%N/A0.039%Search for SEC Filing on Google Icon
8/16/2021Perceptive Advisors LLC2,537,019$39.43M0.5%N/A9.580%Search for SEC Filing on Google Icon
8/16/2021Alyeska Investment Group L.P.175,000$2.72M0.0%N/A0.661%Search for SEC Filing on Google Icon
8/16/2021Charles Schwab Investment Management Inc.18,897$0.29M0.0%N/A0.071%Search for SEC Filing on Google Icon
8/16/2021State Street Corp89,135$1.39M0.0%N/A0.337%Search for SEC Filing on Google Icon
8/16/2021Nuveen Asset Management LLC11,617$0.18M0.0%N/A0.044%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp76,272$1.19M0.0%N/A0.288%Search for SEC Filing on Google Icon
8/13/2021Lumina Fund Management LLC6,000$93K0.0%N/A0.023%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC127,718$1.98M0.0%N/A0.482%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.364,328$5.66M0.0%N/A1.376%Search for SEC Filing on Google Icon
8/13/2021FMR LLC800,000$12.43M0.0%N/A3.021%Search for SEC Filing on Google Icon
8/12/2021Advisory Services Network LLC2,300$36K0.0%N/A0.009%Search for SEC Filing on Google Icon
8/12/2021JPMorgan Chase & Co.2,849$44K0.0%N/A0.011%Search for SEC Filing on Google Icon
8/12/2021Monashee Investment Management LLC20,000$0.31M0.0%N/A0.076%Search for SEC Filing on Google Icon
8/11/2021Bank of New York Mellon Corp13,447$0.21M0.0%N/A0.051%Search for SEC Filing on Google Icon
8/11/2021BlackRock Inc.357,588$5.56M0.0%N/A1.350%Search for SEC Filing on Google Icon
8/11/2021Deutsche Bank AG4,405$68K0.0%N/A0.017%Search for SEC Filing on Google Icon
8/3/2021Victory Capital Management Inc.114,980$1.79M0.0%N/A0.434%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Rain Therapeutics logo
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Read More on Rain Therapeutics

Today's Range

Now: $15.45
Low: $15.45
High: $16.50

50 Day Range

MA: $16.96
Low: $13.21
High: $19.62

52 Week Range

Now: $15.45
Low: $12.90
High: $23.90

Volume

1,813 shs

Average Volume

138,557 shs

Market Capitalization

$408.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Rain Therapeutics?

Rain Therapeutics' top insider shareholders include:
  1. Boxer Capital, Llc (Director)
  2. Bvf Partners L P/Il (Director)
  3. Cormorant Asset Management, Lp (Insider)
  4. Franklin M Berger (Director)
  5. Perceptive Advisors Llc (Major Shareholder)
  6. Value Fund L P Biotechnology (Insider)

Who are the major institutional investors of Rain Therapeutics?

Rain Therapeutics' top institutional investors include:
  1. Perceptive Advisors LLC — 9.58%
  2. Perceptive Advisors LLC — 9.58%
  3. BVF Inc. IL — 7.35%
  4. Samsara BioCapital LLC — 6.18%
  5. Boxer Capital LLC — 4.44%
  6. FMR LLC — 3.02%

Which institutional investors are buying Rain Therapeutics stock?

In the previous quarter, RAIN stock was purchased by institutional investors including:
  1. Perceptive Advisors LLC
  2. Perceptive Advisors LLC
  3. BVF Inc. IL
  4. Samsara BioCapital LLC
  5. Boxer Capital LLC
  6. FMR LLC
  7. Logos Global Management LP
  8. Vanguard Group Inc.
During the last year, these company insiders have bought Rain Therapeutics stock:
  1. Boxer Capital, Llc (Director)
  2. Bvf Partners L P/Il (Director)
  3. Cormorant Asset Management, Lp (Insider)
  4. Franklin M Berger (Director)
  5. Perceptive Advisors Llc (Major Shareholder)
  6. Value Fund L P Biotechnology (Insider)
U.S. healthcare is failing.
Digital Health may be the $245B solutions to fix our healthcare system.
Investors must see why.